NCT03397888View on ClinicalTrials.gov

The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

November 16, 2017

Primary Completion Date

January 16, 2018

Study Completion Date

January 16, 2018

Conditions
Hepatic Impairment
Interventions
DRUG

Betrixaban

80 mg capsule

Trial Locations (1)

33014

Clinical Pharmacology of Miami, Hialeah

Sponsors
All Listed Sponsors
lead

Portola Pharmaceuticals

INDUSTRY

NCT03397888 - The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist | Biotech Hunter | Biotech Hunter